Effect of Salpingectomy During Conservative Hysterectomy
NCT ID: NCT01628432
Last Updated: 2018-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
350 participants
INTERVENTIONAL
2012-07-31
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy
NCT01893086
Impact of Salpingectomy on Ovarian Reserve
NCT02284711
Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology
NCT03187327
A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes
NCT06802198
Effects of Salpingectomy During Laparoscopic Hysterectomy on Ovarian Function
NCT01578759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
the standard procedure during hysterectomy with conservation of the ovaries has been the preservation of fallopian tubes with the clamps placed as close to the uterine corpus as possible. this is suggested to decrease interference with the vascular structures in the mesosalpinx and mesovarium. however it is unclear whether tubal conservation at the time of hysterectomy has any influence on ovarian blood flow or ovarian reserve. another point to be considered is the occurrence of post-hysterectomy carcinoma in the preserved fallopian tube, theoretically, these cases could be prevented if tubal excision is performed during hysterectomy The study compares the effect of bilateral salpingectomy associated with conservative hysterectomy on ovarian function to the standard hysterectomy with conservation of both ovaries and tubes in terms of hormone assays, ovarian ultrasound evaluation, complications, quality of life.
impact of treatments on ovarian reserve are tested by measuring AMH at baseline and 3 days, 6 weeks and 6, 12 months after surgeries.
quality of life is also assessed at these time points, with a questionnaire (Women Health Questionnaire WHQ).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
conservative hysterectomy I
bilateral salpingectomy during hysterectomy with conservation of the ovaries
conservative hysterectomy I
conservative hysterectomy for benign disease
conservative hysterectomy II
standard conservative hysterectomy with conservation of both ovaries and tubes
Conservative hysterectomy II
bilateral salpingectomy during hysterectomy without conservation of the ovaries
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
conservative hysterectomy I
conservative hysterectomy for benign disease
Conservative hysterectomy II
bilateral salpingectomy during hysterectomy without conservation of the ovaries
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* indication of a conservative hysterectomy for benign disease
* signed informed consent
* non menopausal women (AMH \>0,21 ng/ml)
Exclusion Criteria
* desire of future pregnancy
* menopausal status
* patient unable to give informed consent
* any physical or psychiatric condition that could impair with patient's ability to cooperate with post operative data collection
* previous salpingo and /or oophorectomy (unilateral or bilateral)
* genital cancer disease or atypical endometrial hyperplasia
* hyperandrogenia
* any ovarian mass that needs surgical exploration
* any immunotherapy that could interfere with immunological tests
18 Years
52 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lobna OULDAMER, MD
Role: PRINCIPAL_INVESTIGATOR
CHRU de TOURS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU
Angers, , France
CHU
Le Kremlin-Bicêtre, , France
CHU
Lille, , France
Hôpital Sud
Lyon, , France
CHU
Poitiers, , France
CHU
Rennes, , France
CHU
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHRN11/LO/SALPINGOVA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.